Company / R&D Expense
Gilead Sciences R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$5.8B
FY2025
5-year range
$4.1B / $5.9B
FY2021-FY2025
Trend
-1.8%
vs FY2024
Sector context
#8 of 210
Health Care
What the data says
Among 210 Health Care companies, Gilead Sciences is in the top 4% for r&d expense. R&D Expense has fluctuated over the past 10 years, ranging from $2.9B in FY2016 to $5.9B in FY2024.
Based on SEC 10-K filings.
$5.8B in FY2025 with a 5-year CAGR of +3.3%. Top quartile in the Health Care sector.
Improved from $4.6B to $5.8B over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +5.6%
- 5-Year CAGR
- +3.3%
- 10-Year CAGR
- -
Sector benchmark
Top 4% in Health CareTop 4% of 210This company $5.8B Sector average $644.1M
▼
+800.3% above sector average
Key checks
Key Insights
- 5-year CAGR of +3.3%, indicating consistent growth.
- In FY2025, r&d expense decreased 1.8% year-over-year.
- Ranks #8 out of 210 companies in the Health Care sector.
- Peak r&d expense was recorded in FY2024.
Company context
Key Data Points
- Strong profit margin: 27.9%
- Strong return on equity: 37.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $5.8B | -1.8% |
| FY2024 | $5.9B | +28.4% |
| FY2023 | $4.6B | -6.6% |
| FY2022 | $4.9B | +21.5% |
| FY2021 | $4.1B | -17.7% |
| FY2020 | $4.9B | +31.9% |
| FY2019 | $3.7B | -26.8% |
| FY2018 | $5.1B | +69.1% |
| FY2017 | $3.0B | +5.6% |
| FY2016 | $2.9B | -5.3% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026